Search

News

Find here our press releases and most relevant news

News

Press release
- 23.10.2026

New long-term and real-world data on BRIUMVI ® (ublituximab) presented at the 10ᵗʰJoint ACTRIMS-ECTRIMS Meeting 2026

Press release
- 25.09.2026

European Commission grants marketing authorisation for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease

Press release
- 09.09.2026

Minoryx and Neuraxpharm complete enrolment in leriglitazone pivotal Phase 3 trial (CALYX) in adult patients with cerebral Adrenoleukodystrophy (cALD)

Announcement
- 28.07.2026

Neuraxpharm launches its Sustainability Report for 2025

Press release
- 24.07.2026

NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease

Announcement
- 30.05.2026

World MS Day 2026: raising awareness, supporting people living with multiple sclerosis and connecting with the neurology community at EAN Congress 2026

Press release
- 27.05.2026

Positive Topline Results from BRIUMVI® Phase 3 ENHANCE Trial

Announcement
- 22.04.2026

Sant Joan Despí Mayoral Visit to Neuraxpharm

Announcement
- 13.03.2026

World Sleep Day 2026: A Focus on Narcolepsy

Press release
- 17.02.2026

Long-Term/Five-Year Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI ® in Relapsing Multiple Sclerosis

View more

News

Press release
- 23.10.2026

New long-term and real-world data on BRIUMVI ® (ublituximab) presented at the 10ᵗʰJoint ACTRIMS-ECTRIMS Meeting 2026

Press release
- 25.09.2026

European Commission grants marketing authorisation for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease

Press release
- 09.09.2026

Minoryx and Neuraxpharm complete enrolment in leriglitazone pivotal Phase 3 trial (CALYX) in adult patients with cerebral Adrenoleukodystrophy (cALD)

Announcement
- 28.07.2026

Neuraxpharm launches its Sustainability Report for 2025

Press release
- 24.07.2026

NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease

Announcement
- 30.05.2026

World MS Day 2026: raising awareness, supporting people living with multiple sclerosis and connecting with the neurology community at EAN Congress 2026

Press release
- 27.05.2026

Positive Topline Results from BRIUMVI® Phase 3 ENHANCE Trial

Announcement
- 22.04.2026

Sant Joan Despí Mayoral Visit to Neuraxpharm

Announcement
- 13.03.2026

World Sleep Day 2026: A Focus on Narcolepsy

Press release
- 17.02.2026

Long-Term/Five-Year Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI ® in Relapsing Multiple Sclerosis

Announcement
- 09.02.2026

International Epilepsy Day: Every Minute Counts

Press release
- 12.01.2026

Neuraxpharm enhances ADHD treatment options in Europe with two launches

Announcement
- 23.12.2025

End of Year Recap

Press release
- 27.11.2025

Neuraxpharm and mjn-neuro announce plans to launch EPISERAS®, a digital health solution using an AI-powered wearable device for the early detection of epileptic seizures

Announcement
- 12.11.2025

Neuraxpharm: Europe’s CNS Specialist and Partner of Choice

Announcement
- 10.10.2025

Neuraxpharm launches Refocus ADHD campaign for ADHD Month and World Mental Health Day

Press release
- 02.10.2025

Neuraxpharm strengthens multiple sclerosis portfolio with the launch of Riulvy® (tegomil fumarate)

Announcement
- 30.09.2025

Celebrating 40 Years of Neuraxpharm Germany

Press release
- 24.09.2025

New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment

Press release
- 22.09.2025

Neuraxpharm participates in ECTRIMS, reinforcing its commitment to multiple sclerosis

Announcement
- 11.08.2025

Neuraxpharm signs an exclusive distribution agreement with Pendopharm® for Buccolam® in Canada

Announcement
- 07.08.2025

Neuraxpharm launches its Sustainability Report for 2024

Press release
- 23.07.2025

Leriglitazone Marketing Authorization Application submitted for treatment of cerebral adrenoleukodystrophy has been validated by European Medicines Agency

Press release
- 22.07.2025

Neuraxpharm continues international expansion with launch of Neuraxpharm Australia

Press release
- 08.07.2025

Neuraxpharm and Dizlin Pharmaceuticals Announce Global Strategic Co-Development Agreement Bringing Next-Generation Drug-Device Therapy to Patients with Advanced Parkinson’s Disease

Media Enquiries

If you are a journalist with a media enquiry, please contact the Neuraxpharm media office by filling the contact form.

The content you are about to see is intended for the exclusive use of media and healthcare professionals.

Please confirm whether you are a media or a healthcare professiona

I am not a media or healthcare professional

The content you are about to see is intended for the exclusive use of media and healthcare professionals.

Please confirm whether you are a media or a healthcare professional

I am a media or a healthcare professional
I am not a media or healthcare professional